Exhibit H

510(k) Summary

Submitted by: Daniel J. Manelli

Farkas & Manelli, P.L.L.C.

2000 M Street, NW (Suite 700)

Washington, DC 20036

On behalf of Lobob Laboratories, Inc.

510(k) Submission: Optimum Wetting and Rewetting Drop

May 5, 2000

Optimum Wetting and Rewetting Drop by Lobob is intended to wet fluoro-silicone and silicone acrylate rigid gas permeable (RGP) contact lenses prior to insertion and to lubricate lenses while they are on the eye. The product is a sterile solution containing sodium and potassium chloride salts, polyvinyl alcohol, hydroxyethylcellulose, and preserved with benzyl alcohol (10.15%).

The product is substantially equivalent to the currently formulated Lobob Optimum™ Wetting and Rewetting Drop (P940025) and to Stay-Wet® 4, manufactured by Sherman Pharmaceuticals, Inc. (P870029).



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

MAY 2 6 2000

Mr. Daniel J. Manelli Farkas & Manelli PLLC Attorney for Lobob Laboratories, Inc. 2000 M Street #700 Washington, DC 20036

Re: K001428

Trade Name: OPTIMUM Wetting and Rewetting Drop

Regulatory Class: II Product Code: 86 MRC Dated: May 5, 2000 Received: May 5, 2000

Dear Mr. Manelli:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

Page 2 - Mr. Daniel J. Manelli

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-6413. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours,

Mancy C. Brogdon
Nancy C. Brogdon
Acting Director

Division of Ophthalmic and Ear, Nose and Throat Devices Office of Device Evaluation Center for Devices and Radiological Health

		F	Page	<u>1</u> c	of _	1
510(k) Number (if known): <u>k</u>	00 1428					
Device Name: Lobob Opti	imum Wetting	and Rewetting Dro	<u>) </u>			
Indications For Use:						
	tact lenses prid	d silicone acrylate in or to insertion and t the eye.	-			
(Please Do Not Write Below				Need 	led)	
Concurrence of Cl Status (Division Sign-Off Division of Ophthat 510(k) Number	f) almic Devices	Device evaluation (ODE)			
Prescription Use(Per 21 CFR 801.109)	OR	Over-The-Counte	er Use_	-	<u>/</u>	/